Lessons Learned
myelotoxicity
METASTATIC COLORECTAL CANCER
The recommended dose was determined as trifluridine/tipiracil of 35 mg/mBiweekly trifluridine/tipiracil, irinotecan, and bevacizumab administration may have moderate antitumor activity with high risk of severe myelotoxicity in previous treated metastatic colorectal cancer patients.